Clinical Trials Directory

Trials / Unknown

UnknownNCT01655927

Efficacy of Tranexamic Acid in Brain Tumor Resections

PHASE 3 STUDY OF EFFICACY OF TRANEXAMIC ACID IN BRAIN TUMORS RESECTIONS

Status
Unknown
Phase
Phase 3
Study type
Interventional
Enrollment
100 (estimated)
Sponsor
Colombian Foundation for Epilepsy and Neurological Disease · Academic / Other
Sex
All
Age
18 Years – 65 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to determine whether Tranexamic Acid is effective or not in the reduction of intraoperative bleeding loss in brain tumors resections.

Detailed description

Brain tumor resection has been associated with increased blood loss and a significant increase in the incidence of Intravascular disseminated coagulopathy. The development of coagulopathy in the context of tumor resection is associated with poor results. Transfusion decision during the course of neurosurgical surgery offers benefits such as increased oxygen carrying capacity but may increase the risk associated with transfusions such as blood infections, hemolysis, lung injury and immunosuppression. The information available on tranexamic acid used in neurosurgery is little, therefore this opens up new alternatives in the techniques of reducing intraoperative bleeding. Tranexamic acid is an antifibrinolytic agent that blocks the binding of plasminogen to the fibrin surface. It has been used to reduce blood loss during coronary revascularization, liver resection, obstetrics and orthopedic procedures. Tranexamic acid intraoperatively has been shown to reduce blood loss up to 45%. The primary concern when administering an antifibrinolytic drug is the potential increased incidence of thromboembolic events. There is no actual data on the utility of tranexamic acid to reduce blood loss in brain tumors resection surgery. We want to compare Tranexamic Acid to Saline solution(Placebo) to see whether Tranexamic ACid Administration will reduce blood loss during brain tumor resection. Reduction in transfusion requirements will lead to reduced costs and possible reduction in complications of blood transfusion and perioperative incidents.

Conditions

Interventions

TypeNameDescription
DRUGTranexamic Acid
DRUGPlacebo: Saline

Timeline

Start date
2012-07-01
Primary completion
2013-07-01
First posted
2012-08-02
Last updated
2012-08-02

Locations

1 site across 1 country: Colombia

Source: ClinicalTrials.gov record NCT01655927. Inclusion in this directory is not an endorsement.

Efficacy of Tranexamic Acid in Brain Tumor Resections (NCT01655927) · Clinical Trials Directory